The design, analysis and application of mouse clinical trials in oncology drug development
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The design, analysis and application of mouse clinical trials in oncology drug development
Authors
Keywords
PDX, CDX, Syngeneic model, Mouse clinical trials, Linear mixed models, Survival analysis, Statistical power, Biomarker
Journal
BMC CANCER
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-22
DOI
10.1186/s12885-019-5907-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field
- (2018) Juliet Williams Journal of Clinical Medicine
- Orthotopic patient-derived xenografts of paediatric solid tumours
- (2017) Elizabeth Stewart et al. NATURE
- Experimental animal modeling for immuno-oncology
- (2017) Qi-Xiang Li et al. PHARMACOLOGY & THERAPEUTICS
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
- (2016) Elizabeth C. Townsend et al. CANCER CELL
- Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines
- (2016) S. Guo et al. CANCER RESEARCH
- Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
- (2016) Brendan Murphy et al. CANCER RESEARCH
- NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors
- (2016) Mengmeng Yang et al. INTERNATIONAL JOURNAL OF CANCER
- Optimized design and analysis of preclinical intervention studies in vivo
- (2016) Teemu D. Laajala et al. Scientific Reports
- Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
- (2016) Suzanne I.S. Mosely et al. Cancer Immunology Research
- Tumor profiling of gastric and esophageal carcinoma reveal different treatment options
- (2015) John T Miura et al. CANCER BIOLOGY & THERAPY
- Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
- (2015) Chi-Ping Day et al. CELL
- The genomic landscape of response to EGFR blockade in colorectal cancer
- (2015) Andrea Bertotti et al. NATURE
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
- (2015) Hui Gao et al. NATURE MEDICINE
- Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial
- (2014) Xiaotian Zhang et al. MEDICAL ONCOLOGY
- STRING v10: protein–protein interaction networks, integrated over the tree of life
- (2014) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- Cancer mouse models: Past, present and future
- (2014) Walid T. Khaled et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth
- (2014) Sébastien Benzekry et al. PLoS Computational Biology
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
- (2013) Edward Y Chen et al. BMC BIOINFORMATICS
- A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker
- (2013) Masahiro Hirakawa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
- (2013) Sara De Dosso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
- (2013) Lianhai Zhang et al. Scientific Reports
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients
- (2012) Mengmeng Yang et al. INTERNATIONAL JOURNAL OF CANCER
- Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer
- (2012) Amir Sonnenblick et al. MEDICAL ONCOLOGY
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
- (2010) Ki Han Kim et al. BIOMARKERS
- A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer
- (2010) Aristotelis Bamias et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More